Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial by Ledermann, Jonathan A, Prof, Embleton, Andrew C, MSc, Raja, Fharat, BMBCh, Perren, Timothy J, Prof, Jayson, Gordon C, Prof, Rustin, Gordon J S, Prof, Kaye, Stan B, Prof, Hirte, Hal, MD, Eisenhauer, Elizabeth, Prof, Vaughan, Michelle, MB, Friedlander, Michael, Prof, González-Martín, Antonio, MD, Stark, Daniel, MD, Clark, Elizabeth, BSc, Farrelly, Laura, MSc, Swart, Ann Marie, Prof, Cook, Adrian, MSc, Kaplan, Richard S, Prof, Parmar, Mahesh K B, Prof

Get full text

Outcomes and endpoints in cancer trials: bridging the divide by Wilson, Michelle K, FRACP, Collyar, Deborah, BSc, Chingos, Diana T, MFA, Friedlander, Michael, Prof, Ho, Tony W, MD, Karakasis, Katherine, MSc, Kaye, Stan, Prof, Parmar, Mahesh K B, Prof, Sydes, Matthew R, CStat, Tannock, Ian F, Prof, Oza, Amit M, Prof

Get full text

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial by Sandhu, Shahneen K, MD, Schelman, William R, MD, Wilding, George, MD, Moreno, Victor, MD, Baird, Richard D, PhD, Miranda, Susana, BSc, Hylands, Lucy, BSc, Riisnaes, Ruth, FIBMS, Forster, Martin, PhD, Omlin, Aurelius, MD, Kreischer, Nathan, MSc, Thway, Khin, MD, Gevensleben, Heidrun, MD, Sun, Linda, PhD, Loughney, John, PhD, Chatterjee, Manash, PhD, Toniatti, Carlo, PhD, Carpenter, Christopher L, MD, Iannone, Robert, MD, Kaye, Stan B, Prof, de Bono, Johann S, Prof, Wenham, Robert M

Get full text